Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals LtdfiledCriticalActelion Pharmaceuticals Ltd
Publication of AR070457A1publicationCriticalpatent/AR070457A1/en
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Combinacion de bosentan con paclitaxel, y en particular con su combinacion para uso terapéutico, de manera simultánea, separada o durante un período de tiempo, en el tratamiento de cáncer de ovarios. Su uso.Combination of bosentan with paclitaxel, and in particular with its combination for therapeutic use, simultaneously, separately or for a period of time, in the treatment of ovarian cancer. Its use.
ARP090100597A2008-02-202009-02-20
COMBINATION THAT INCLUDES BOSENTAN FOR THE TREATMENT OF CANCER OF OVARIO
AR070457A1
(en)
Compounds derived from chromen-2-one; pharmaceutical composition that includes them; and their use in the treatment of a proliferative disorder such as cancer.
Compounds derived from picolinamide, pim kinase inhibitors, associated with tumorigenesis; pharmaceutical composition that includes them; and its use in the treatment of cancer.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
Immunostimulatory oligonucleotide; pharmaceutical composition comprising it; and its use to treat a disorder or condition in a subject, including cancer.
Use of an anti-cd20 type II antibody useful to prepare a drug to treat a cancer that expresses cd20 in combination with a proteasome inhibitor, pharmaceutical composition containing said combination and kit of the same
Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.
COMPOUNDS DERIVED FROM PIRIDINA, INHIBITORS OF THE P2Y12 RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE PLAQUETARY AGREGATION DISORDER.